StockData
Relay Therapeutics, Inc. logo

Relay Therapeutics, Inc. (RLAY) stock

RLAYNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 10/30
$15.91−0.60 (-3.63%)

Close on Nov 19, 2026Market cap $3.49BP/E –Yield –

Relay Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Relay Therapeutics's free cash flow for the twelve months ending Dec 31, 2025 was -$235.87M. For fiscal 2025 it was -$235.87M. The highest annual figure on record is -$74.14M in fiscal 2019.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$235.87M–
FY2024Dec 31, 2024-$251.13M–
FY2023Dec 31, 2023-$304.44M–
FY2022Dec 31, 2022-$238.55M–
FY2021Dec 31, 2021-$77.88M–
FY2020Dec 31, 2020-$104.42M–
FY2019Dec 31, 2019-$74.14M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2025Dec 31, 2025-$44.87M–
Q3 FY2025Sep 30, 2025-$62.12M–
Q2 FY2025Jun 30, 2025-$55.29M–
Q1 FY2025Mar 31, 2025-$73.59M–
Q4 FY2024Dec 31, 2024-$57.87M–
Q3 FY2024Sep 30, 2024-$75.31M–
Q2 FY2024Jun 30, 2024-$65.84M–
Q1 FY2024Mar 31, 2024-$52.10M–
Q4 FY2023Dec 31, 2023-$89.31M–
Q3 FY2023Sep 30, 2023-$75.99M–
Q2 FY2023Jun 30, 2023-$70.10M–
Q1 FY2023Mar 31, 2023-$69.05M–
Q4 FY2022Dec 31, 2022-$59.40M–
Q3 FY2022Sep 30, 2022-$68.24M–
Q2 FY2022Jun 30, 2022-$58.95M–
Q1 FY2022Mar 31, 2022-$51.97M-212.6%
Q4 FY2021Dec 31, 2021-$40.59M–
Q3 FY2021Sep 30, 2021-$54.94M–
Q2 FY2021Jun 30, 2021-$28.52M–
Q1 FY2021Mar 31, 2021$46.16M–
Q4 FY2020Dec 31, 2020-$35.34M–
Q3 FY2020Sep 30, 2020-$24.47M–
Q2 FY2020Jun 30, 2020-$21.26M–
Q1 FY2020Mar 31, 2020-$23.35M–
Q4 FY2019Dec 31, 2019-$23.36M–
Q3 FY2019Sep 30, 2019-$19.89M–

More Relay Therapeutics figures

See a number that looks wrong?